Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by Fretz et al., ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

With blockbuster GLP-1 drugs such as Ozempic, Wegovy from Danish drug maker Novo Nordisk, and Mounjaro from American pharma ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.